| Date | Title | Description |
| 18.09.2026 | Startup Funding News Today, September 18, 2026: Arcos, Crusoe, dtcpay, EVAS Intelligence, Ryft & More | Startup funding over the past day is being pulled toward a surprisingly consistent set of bottlenecks: AI compute, sovereign chips, power systems, optical interconnects, robotics data, quantum infrastructure, security, and regulated payment... |
| 17.09.2026 | Health Tech Surges. Markets Adapt. | Evvy secures $40 million Series B funding. This capital propels AI-driven women's health innovation, focusing on advanced fertility diagnostics and personalized care pathways. The substantial investment highlights robust venture capital con... |
| 16.09.2026 | Evvy Secures $40M Series Round |
NEW YORK, NY, Evvy, the pioneering precision medicine company for women's health, has announced an oversubscribed $40 million Series B led by Catalio Capital Management.
>> Click here for more funding data on Evvy
>> To export ... |
| 15.09.2026 | Evvy Raises $40M to Expand AI Women’s Health Diagnostics | Evvy Raises $40M To Advance Precision Women’s Health
Evvy has raised $40 million in Series B funding to expand its precision medicine platform for women’s health. Catalio Capital Management led the oversubscribed round. Rethink Impact and M... |
| 03.09.2026 | Superluminal Medicines Raises $60M in Series B Funding | Superluminal Medicines, a Boston, MA-based biotechnology company integrating AI/ML, protein dynamics, and structural biology to generate G protein-coupled receptor (GPCR) targets, raised $60M in Series B financing.
The round was led by BVF ... |
| 03.08.2026 | Ratio Therapeutics Raises $70M in Series C Funding | Ratio Therapeutics, a Boston, MA-based provider of a radiopharmaceutical platform developing targeted cancer treatments, raised $70M in Series C funding.
Backers included Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Managem... |
| 03.08.2026 | Claris Biotherapeutics Raises $118M in Series B Funding | Claris Biotherapeutics, Inc., a Jersey City, NJ-based biopharmaceutical company developing therapies for sight-threatening conditions, raised $118M in Series B financing.
The round was led by Samsara Biocapital and Catalio Capital Managemen... |
| 16.07.2026 | AdvanCell Closes $315 Million Series D |
BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscribed and upsized $315 million Series D financing.
>> Click here for more funding data on AdvanCell
>> To export AdvanCel... |
| 15.07.2026 | AdvanCell Closes US $315M in Series D Funding | AdvanCell, a Boston, MA- and Brisbane, Australia-based clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised US $315M Series D in funding.
The round was led by Ally Bridge Group and Alpha Wave, al... |
| 15.07.2026 | AdvanCell Closes $315 Million Series D Financing To Advance Targeted Alpha Therapies | AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, announced the closing of an oversubscribed and upsized $315 million Series D financing. The round was led by Ally Bridge Group and co-le... |
| 14.05.2026 | 9amHealth Secures $26M Series B for Virtual Chronic Care Expansion | 9amHealth, a leader in AI-driven virtual specialty care, secured $26 million in Series B funding. This investment propels its expansion beyond cardiometabolic conditions. The company targets a broader spectrum of high-cost chronic diseases.... |
| 13.05.2026 | 9amHealth Raises $26M to Expand AI-Driven Virtual Specialty Care for Chronic Conditions | What You Should Know
9amHealth has secured $26M in Series B funding led by Define Ventures, bringing new participation from SemperVirens, Catalio Capital Management, and NewHealth Ventures.
The platform has demonstrated over $50 million in ... |
| 13.05.2026 | 9amHealth Raises $26M in Series B Funding | 9amHealth, a San Diego, CA-based virtual specialty care platform provider, raised $26M in Series B funding.
The round was led by Define Ventures, with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures.
L... |
| 13.05.2026 | 9amHealth: $26 Million Series B Raised To Expand Virtual Specialty Care | 9amHealth announced a $26 million Series B financing round led by Define Ventures, with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures. The company said the funding will support expansion of its AI-en... |
| 07.01.2026 | Credit Over Equity: Catalio Capital’s $325M Fund Signals a New Financial Playbook for Healthcare Innovation | What You Should Know
– Catalio Capital Management has closed its second credit fund with over $325M in commitments, marking a significant expansion of structured financing options for commercial-stage healthcare companies.
– As traditional ... |
| 18.11.2025 | Beacon Biosignals Secures $86M to Revolutionize Brain Disorder Treatment | Beacon Biosignals landed $86M in Series B funding. They plan to use it to improve diagnostics and treatment using AI. Their neurotechnology targets brain disorders. The funding helps them expand and accelerate discovery. This positions them... |
| 16.11.2025 | Beacon Biosignals: $86 Million Series B Raised To Advance AI-Driven Neurodiagnostics And Precision Neuroscience | Beacon Biosignals has raised an oversubscribed $86 million Series B to accelerate the clinical adoption of AI-powered biomarkers for neurological and psychiatric disease, expand its precision medicine data platform, and scale its neurodiagn... |
| 13.11.2025 | Beacon Biosignals Raises $86M in Series B Funding | Beacon Biosignals, a Boston, MA-based neurotechnology company powering AI-driven diagnostics and precision medicines for the brain, raised $86m in Series B funding.
Backers included Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, ... |
| 12.11.2025 | AI-Driven Biotech Iambic Secures Over $100M for Drug Discovery | Iambic, a San Diego AI-driven biotech, secured over $100M in funding. This capital fuels its advanced AI drug discovery platform and expanding clinical pipeline. The company rapidly advances novel therapies, like IAM1363, showing strong ant... |
| 10.11.2025 | Iambic: $100 Million Raised To Advance AI-Discovered Therapeutics And Platform Technologies | Iambic, a clinical-stage life science and technology company headquartered in San Diego, announced that it has raised more than $100 million in an oversubscribed financing round. The round drew participation from a broad group of new and ex... |
| 19.10.2025 | Lila: $350 Million Series A Raised To Advance Development Of Scientific Superintelligence Platform | Lila Sciences, an AI company dedicated to building scientific superintelligence to solve humanity’s most complex challenges, has announced the completion of a $350 million Series A round, bringing its total funding to $550 million. The fund... |
| 17.10.2025 | Cartography Biosciences: $67 Million Series B Closed For Advancing Novel Antibody-Based Oncology Therapies | Cartography Biosciences, a precision oncology company developing next-generation T-cell engaging antibody therapeutics, announced it has closed a $67 million Series B financing to accelerate its differentiated pipeline toward the clinic. Th... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 02.10.2025 | Cartography Raises $67M in Series B Funding | Cartograpgy, a San Francisco, CA-based oncology company advancing a pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics that target novel and highly specific tumor antigens, raised $67M in Series B funding.
The r... |
| 01.10.2025 | Leo Cancer Care Secures $40M, Ignites Upright Radiotherapy Revolution | Leo Cancer Care secured $40M in a landmark funding round. Catalio Capital Management led the investment. This capital fuels aggressive commercialization of the innovative Marie® upright radiotherapy system. The technology transforms cancer ... |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding.
The round was co-led by Sanofi Ventures and Vi... |
| 29.09.2025 | Leo Cancer Care Raises $40M in Funding | Leo Cancer Care, a Middleton, WI-based radiotherapy treatment devices company, raised $40M in funding.
The round was led by Catalio Capital Management. As part of the funding round, Catalio’s Dr. Nicholas von Guionneau, joins Leo Cancer Car... |
| 26.09.2025 | Ensoma Secures $53M to Accelerate In Vivo Stem Cell Gene Therapies | Ensoma has secured $53 million in a pivotal funding round. This capital infusion accelerates its groundbreaking work in one-time, in vivo stem cell therapies. A primary goal involves progressing the Phase 1/2 clinical trial for EN-374, spec... |
| 24.09.2025 | Leo Cancer Care Secures $40M to Commercialize Upright Radiotherapy System | What You Should Know:
– Leo Cancer Care, a pioneer in radiotherapy treatment devices, has successfully raised $40M in funding round led by Catalio Capital Management.
– The investment, which also saw participation from new and existing inve... |
| 23.09.2025 | Ensoma Raises $53M in Funding | Ensoma, a Boston, MA-based in vivo hematopoietic stem cell (HSC) engineering company, raised $53M in funding.
Backers included Gilead (Nasdaq: GILD), which has also appointed an executive to the Ensoma board of directors as part of its inve... |
| 23.09.2025 | Ensoma: $53 Million Secured To Advance Stem Cell Therapies And Global Clinical Impact | Ensoma, a biotechnology company focused on transforming medicine through one-time, in vivo stem cell therapies, has announced the closing of a $53 million funding round. This investment comes from a group of leading investors who have previ... |
| 18.09.2025 | Character Biosciences Expands Series B Extension | Character Biosciences, Jersey City, NJ-based precision medicine company, raised an undisclosed amount in Series B extension.
Backers included Sanofi Ventures.
The company intends to use the funds to further advance the clinical development ... |
| 19.08.2025 | OSPRI Launches as Vertically-Integrated Biotech Company with $30M | What You Should Know:
– Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics have merged to form OSPRI, a new biotechnology company specializing in polymerase chain reaction (PCR)-based infectious disease detec... |
| 13.08.2025 | Amalgam Rx Secures $20M for AI Healthcare Expansion | Amalgam Rx, a leader in data-driven healthcare, secured a significant $20 million credit investment from Catalio Capital Management. This strategic funding fuels the rapid expansion of its advanced Medical-Grade AI platform. Capital specifi... |
| 12.08.2025 | Amalgam Rx Raises $20M in Credit Investment from Catalio Capital Management | Amalgam RX, a Wilmington, DE-based company enabling data-driven healthcare decision making, raised £20M in Credit Investment.
Catalio Capital Management made the investment.
The company intends to use the funds to scale its Medical-Grade AI... |
| 12.08.2025 | Amalgam Rx Secures $20M to Accelerate AI-Powered Healthcare Solutions | What You Should Know:
– Amalgam Rx, a company specializing in data-driven healthcare decision-making, has announced a $20M credit investment from Catalio Capital Management.
– The $20M senior secured term loan provides Amalgam with an initi... |
| 01.07.2025 | Catalio Capital Management Closes $400M+ Fund IV to Fuel Breakthrough Biomedical Innovation | What You Should Know:
– Catalio Capital Management, LP (“Catalio”), a healthcare investment firm, today announced the successful close of its fourth venture fund, Catalio Nexus Fund IV (“Fund IV”), with over $400M in commitments across the ... |
| 30.05.2025 | GlycoEra AG: Pioneering a New Era in Autoimmune Disease Treatment | In the world of biotechnology, innovation is the lifeblood that fuels progress. GlycoEra AG is a shining example of this principle. Recently, the company secured $130 million in funding to advance its groundbreaking therapies for autoimmune... |
| 27.05.2025 | GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases |
GlycoEra’s proprietary platform enables the development of best-in-class degraders that target a broad spectrum of extracellular proteins. GlycoEra’s degraders are bispecific molecules that leverage a naturally occurring process to degrade... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA
Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| 06.11.2024 | PrognomiQ's $34 Million Boost: A New Dawn for Lung Cancer Detection | In the realm of healthcare, innovation is the lifeblood that fuels progress. PrognomiQ, a rising star in the diagnostics industry, has just secured a significant $34 million in Series D funding. This financial windfall, led by Seer, Inc., m... |
| 05.11.2024 | PrognomiQ Raises $34M to Advance Multi-Omics Early Detection Test for Lung Cancer | What You Should Know:
– PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has secured $34M in Series D funding led by Seer, Inc., with participation from a new strategic investor and existing investors ... |
| 13.08.2024 | Australian biotech incubator Proto Axiom announces $20M Series B first close | $20M unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at $90M
SYDNEY, Aug. 13, 2024 /PRNewswire/ -- Proto Axiom, the Australian biomedical technology incubator has today announced a $20 million first close of... |
| 12.03.2024 | Texas-based 'hop-on' jet service offers exclusive eclipse flight flown by NASA pilot | With Texas set to be the prime location for the Great North American Solar Eclipse, airlines are lining up to offer the best vantage point and that includes JSX: The private carrier is offering a once-in-a-lifetime in-flight experience to 1... |
| 12.03.2024 | Houston health tech company announces $10M in fresh funding to bolster customer care | Roshal Health, a Katy-based provider of ultrasound and echocardiogram services for health care facilities, has secured $10 million in structured equity financing.
New York City-based investment firm Catalio Capital Management led the financ... |
| 29.08.2023 | TapestryHealth Secures $25M Credit Investment | What You Should Know:
TapestryHealth, a multi-specialty healthcare company, announced a $25M credit investment from Catalio Capital Management, a leading multi-strategy investment firm focused on healthcare and life sciences.
The senior sec... |
| 17.05.2022 | Character Biosciences Raises $18M to Expand Precision Medicine Platform for Diseases of Aging | What You Should Know:
– Character Biosciences (“Character”), a precision medicine platform for diseases of aging raises $18M in a new funding round led by Innovation Endeavors, alongside leading life sciences investors Section 32 and Catali... |
| 04.05.2022 | Catalio snags over $381M for Fund III | Catalio Capital Management has closed its third life sciences fund with more than $381 million in capital commitments, surpassing a target of $300 million. The fund will be used to back biomedical tech companies at all stages of growth. Ope... |
| 04.05.2022 | Catalio reloads with $381M after financing Octant, Pheast | Catalio Capital Management, the life sciences investment firm behind recent funding rounds from Pheast Therapeutics, Octant and more, has reloaded with another $381 million—its largest fund to date to support breakthrough biotech companies.... |
| 03.05.2022 | Catalio Capital Management closes $381M venture fund | Biomedical industry-focused investment firm Catalio Capital Management today announced the close of a venture fund that its cofounder says will help it grow Baltimore’s own life sciences industry.
The Catalio Nexus Fund III is worth $381 mi... |
| 03.05.2022 | Catalio Capital Management Closes $381M Third Life Sciences Fund | Catalio Capital Management, LP, a NYC-based multi-strategy life sciences investment firm, closed its third venture fund, Catalio Nexus Fund III, at more than $381m.
The fund received backing from current investors and a number of new, globa... |
| 03.05.2022 | This private equity firm is sharing returns with portfolio company employees | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
When a record number of people are quitting their jobs, it may help to give employees a stake in ... |
| 06.10.2021 | Starting a health technology company in Baltimore? Here are 43 resources to know | The digital health sector was growing rapidly. Then the pandemic came.
In this case, it was a story of growth.
Following distancing requirements and loosening regulations, telemedicine became the name of the game for many healthcare systems... |
| 03.02.2021 | Catalio Capital Management launches credit strategy, hires 2 Brown Advisory portfolio managers | Biomedical-focused investment firm Catalio Capital Management is launching a new credit strategy that will provide non-dilutive capital to companies, and brought on a pair of former portfolio managers from Baltimore-based Brown Advisory to ... |
| 28.01.2021 | Money Moves: The Baltimore connection to a $180M SPAC IPO | A Baltimore-based biomedical investment firm is one of the partners on a blank check company that debuted on the Nasdaq this week.
HealthCor Catalio Acquisition Corp. started trading shares Wednesday as it raised $180 million in an initial ... |
| 10.12.2020 | Catalio Capital Join $81 Million Series A for Faze Medicines | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced its launch and Series A financing of $81 million. Faze i... |
| 16.10.2020 | Need startup funding? Here are 75+ venture capital firms in the Baltimore-DC region | If you’re located in New York City or the Silicon Valley, venture capital firms are abundant and well covered by the media — you can’t escape them. But entrepreneurs in the Baltimore-D.C. region don’t need to go so far to find a firm that c... |
| 13.10.2020 | Need startup funding? Here are 75+ venture capital firms in the DMV region | If you’re located in New York City or the Silicon Valley, venture capital firms are abundant and well covered by the media — you can’t escape them. But entrepreneurs in the DMV region don’t need to go so far to find a firm that could propel... |
| 06.10.2020 | Catalio Capital Management Closes Venture Fund II, at $100M | Catalio Capital Management, LP, a NYC-based life sciences investment firm, closed its second venture fund, Catalio Nexus II, at $100m.
The fund received support from private equity and hedge fund investors, as well as institutional family o... |
| 06.10.2020 | Catalio Capital Management LP : Closes Oversubscribed Venture Fund II at $100 Million Hard Cap | Catalio Capital Management LP (Catalio), a prominent life sciences investment firm, announced today the close of its second venture fund, Catalio Nexus II. The fund was oversubscribed and closed at its hard cap of $100 million, backed by pr... |
| 06.10.2020 | Catalio Capital Management Closes Venture Fund II at $100 Million Hard Cap | NEW YORK--(BUSINESS WIRE)--Catalio Capital Management LP, a prominent life sciences investment firm, announced today the close of its second venture fund, Catalio Nexus II. The fund was oversubscribed and closed at its hard cap of $100 mill... |
| 06.10.2020 | Catalio Capital Management closes $100M venture fund | Catalio Capital Management, a Baltimore-based investment firm focused on biomedical technology companies, said Tuesday that it closed its second venture fund with $100 million.
The fund, called Catalio Nexus II, was oversubscribed. Backed b... |
| 06.10.2020 | Baltimore venture capital firm Catalio Capital Management closes $100M fund | Catalio Capital Management LP, a Baltimore biotechnology-focused investment firm that recently spun out of Camden Partners, has closed a new fund worth $100 million.
The fund was oversubscribed and closed at its cap of $100 million. Partici... |
| - | French biotech DNA Script raises $200 million, pushes forward with desktop DNA printer | Parisian life sciences technology company DNA Script has raised $200 million in a Series C funding round. The company has developed an alternative to traditional DNA synthesis, a proprietary mechanism it calls Enzymatic DNA Synthesis. This ... |
| - | Sanguine Biosciences: $10 Million Credit Financing Provided By Catalio Capital Management | Sanguine Biosciences – a leading biospecimen procurement services company that empowers patients to accelerate precision medicine and cell and gene therapy research and development – recently announced that it secured $10 million in credit ... |
| - | Healthcare VC firms that backed the COVID shot and cancer treatments are now placing bets on psychedelics | Psilocybin mushrooms on a mossy log. jackfoto/iStock/Getty Images Plus This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Companies developing psychedelics-based drugs need lots of cash in o... |
